Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity

Molecular Cancer Therapeutics

Volumn 3, Issue 2, 2004, Pages 103-110

  Jansen, Aaron P ^a   Camalier, Corinne E ^a   Stark, Cristi ^a   Colburn, Nancy H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCOMYCIN; BLEOMYCIN; CARMUSTINE; CISPLATIN; COMPLEMENTARY DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GELDANAMYCIN; INITIATION FACTOR 4A; LOMUSTINE; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; PROGRAMMED CELL DEATH 4; TAMOXIFEN; TIOGUANINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VINBLASTINE SULFATE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CENTER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG SENSITIVITY; ENHANCER REGION; GLIOMA; HUMAN; HUMAN CELL; KIDNEY CANCER; KIDNEY TUMOR; LUNG TUMOR; MULTIPLE CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; TRANSLATION INITIATION; UPREGULATION; WESTERN BLOTTING;

EID: 4444285717     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.103.3.2     Document Type: Article

References (44)

1. Yang H-S, Jansen AP, Nair R, Shibara K, Verma AK, Cmarik JL, et al. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kB or ODC transactivation. Oncogene, 2001;20:669-76.
2. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev, 2001;21:146-70.
3. Matrisian LM, McDonnell S, Miller DB, Navre M, Seftor EA, Hendrix MJ. The role of the matrix metalloproteinase stromelysin in the progression of squamous cell carcinomas. Am J Med Sci, 1991;302:157-62.
4. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J, 1999;13:781-92.
5. Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, et al. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA, 1999;96: 14037-42.
6. Yang HS, Knies JL, Stark C, Colburn NH. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene, 2003;22:3712-20.
7. Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Coates S, et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol, 2003;23:26-37.
8. Young MR, Li JJ, Rincon M, Flavell RA, Sathyanarayana BK, Hunziker R, et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci USA, 1999;96:9827-32.
9. Eberle J, Krasagakis K, Orfanos CE. Translation initiation factor eIF4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. Int J Cancer, 1997;71:396-401.
10. De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol, 1999;31: 59-72.
11. Bauer C, Diesinger I, Brass N, Steinhart H, Iro H, Meese EU. Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. Cancer, 2001;92:822-9.
12. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell, 1990;61:759-67.
13. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet, 1993;9:138-41.
14. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell, 2000;100: 57-70.
15. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst, 1991;83:757-66.
16. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst, 1989;81:1088-92.
17. Paull KD, Lin CM, Malspeis L, Hamel E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res, 1992;52:3892-900.
18. Boyd M, Paull K, Rubinstein L, editors. Data display and analysis strategies for the NCI disease oriented in vitro antitumor drug screen. Boston: Kluwer Academic Publishers. 1992. p. 11-34.
19. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Graver M, et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol, 1994;46:627-38.
20. Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des, 1997;12:533-41.
21. Nusse M, Beisker W, Hoffmann C, Tarnok A. Flow cytometric analysis of G1- and G2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements. Cytometry, 1990;11:813-21.
22. Macleod K. Tumor suppressor genes. Curr Opin Genet Dev, 2000; 10:81-93.
23. Quon KC, Berns A. Haplo-insufficiency? Let me count the ways. Genes Dev, 2001;15:2917-21.
24. Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z. Novel human PDCD4(H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int, 1999;49:1067-77.
25. Ross DT, Scharf U, Eisen MB, Perou CM, Rees C, Spellman P, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet, 2000;24:227-35.
26. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet, 2000;24:236-44.
27. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature, 1998; 396:177-80.
28. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J, 1998;17:4657-67.
29. Shibahara K, Asano M, Ishida Y, Aoki T, Koike T, Honjo T. Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene, 1995;166:297-301.
30. Onishi Y, Kizaki H. Molecular cloning of the genes suppressed in RVC lymphoma cells by topoisomerase inhibitors. Biochem Biophys Res Commun, 1996;228:7-13.
31. Matsuhashi S, Yoshinaga H, Yatsuki H, Tsugita A, Hori K. Isolation of a novel gene from a human cell line with Pr-28 MAb which recognizes a nuclear antigen involved in the cell cycle. Res Commun Biochem Cell Mol Biol, 1997;1:109-20.
32. Azzoni L, Zatsepina O, Abede B, Bennett IM, Kanakaraj P, Perussia B. Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. J Immunol, 1998;161:3493-500.
33. Kang MJ, Ahn HS, Lee JY, Matsuhashi S, Park WY. Up-regulation of PDCD4 in senescent human diploid fibroblasts. Biochem Biophys Res Commun, 2002;293:617-21.
34. Onishi Y, Hashimoto S, Kizaki H. Cloning of the TIS gene suppressed by topoisomerase inhibitors. Gene, 1998;215:453-9.
35. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth & Differ, 2000;11:355-60.
36. Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, Soga S, et al. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood, 2000;96:2284-91.
37. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood, 2002;100:3041-4.
38. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem, 1996;271:22796-801.
39. Baulieu EE, Binart N, Cadepond F, Catelli MG, Chambraud B, Garnier JM, et al. Thyroid hormone receptor family and gene regulation. In: Gustafsson JA, Eriksson H, Carlstedt-Duke J, editors. The steroid. Basel: Birkhauser, 1989. p. 301-18.
40. Schulte TW, An WG, Neckers LM. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun, 1997;239:655-9.
41. Whitesell L, Sutphin P, An WG, Schulte T, Blagosklonny MV, Neckers L. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo Oncogene, 1997;14:2809-16.
42. Chen Y, Knosel T, Kristiansen G, Pietas A, Garber ME, Matsuhashi S, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol, 2003;200:640-6.
43. Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res, 2000;60:3940-6.
44. Munster PN, Srethapakdi M, Moasser MM, Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res, 2001;61: 2945-52.